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Abstract
Background: The fractional exhaled nitric oxide (FENO) test is a
point-of-care test that is used in the assessment of asthma.
Objective: To provide evidence-based clinical guidance on
whether FENO testing is indicated to optimize asthma treatment
in patients with asthma in whom treatment is being considered.
Methods: An international, multidisciplinary panel of experts
was convened to form a consensus document regarding a single
question relevant to the use of FENO. The question was selected
from three potential questions based on the greatest perceived
impact on clinical practice and the unmet need for evidence-
based answers related to this question. The panel performed
systematic reviews of published randomized controlled trials
between 2004 and 2019 and followed the Grading of
Recommendations, Assessment, Development, and Evaluation
(GRADE) evidence-to-decision framework to develop
recommendations. All panel members evaluated and approved
the recommendations.
Main Results: After considering the overall low quality of the
evidence, the panel made a conditional recommendation for
FENO-based care. In patients with asthma in whom treatment is
being considered, we suggest that FENO is beneficial and should
be used in addition to usual care. This judgment is based on a
balance of effects that probably favors the intervention; the
moderate costs and availability of resources, which probably
favors the intervention; and the perceived acceptability and
feasibility of the intervention in daily practice.
Conclusions: Clinicians should consider this recommendation
to measure FENO in patients with asthma in whom treatment is
being considered based on current best available evidence.
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type 2 inflammation
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Introduction
Asthma is a heterogeneous disease that
causes variable airflow obstruction and
features of airway hyperresponsiveness
(AHR) in response to a variety of triggers,
including respiratory viral infections,
environmental allergens, and physical stimuli
such as exercise with its accompanying
hyperpnea (1, 2). It is generally well accepted
that underlying inflammation of the airways
acts in conjunction with structural changes
collectively known as airway remodeling to
form the pathophysiology of the disease (3).
Treatment decisions are typically based on
measures of airflow obstruction, the
frequency of daytime and nighttime
symptoms, and the frequency of
exacerbations (1, 2). Individuals with
persistent symptoms, or with airflow
obstruction at lung function testing and/or
who experience asthma exacerbations, are
typically treated with daily controller
therapies such as inhaled corticosteroids
(ICSs) with or without a long-acting
b-agonist and/or a leukotriene modifier or
long-acting muscarinic antagonist (4, 5). In
individuals with uncontrolled asthma,
biologic therapies targeting specific
inflammatory pathways (e.g., monoclonal
antibodies targeting type 2 [T2]
inflammation) are considered. Treatment is
adjusted on the basis of the level of asthma
control that is achieved with the selected
therapy; however, the response to therapy is
heterogeneous. Clinicians are in need of
complementary tools that can assist them in
making informed treatment decisions about
the type and intensity of daily controller
therapy.
Once the diagnosis of asthma is
established, selecting the type of therapy and
selecting the optimal dose of therapy for the
patient are challenging decisions faced by
clinicians. Therapies such as ICSs improve
lung function and asthma control, decrease
daytime and nighttime symptoms, and
reduce the frequency of asthma
exacerbations (6, 7). However, a significant
portion of patients do not have a substantive
response to therapy, and the response of an
individual patient to a given dose of therapy
is variable (8–13). Methods that have been
developed to further assess the level of airway
inflammation to guide corticosteroid
responsiveness, such as inducing sputum to
measure eosinophils, are not widely available
(14–18). Other measures such as AHR
(19–21) and peak expiratory flow variability
(22) can also provide information that is
useful to clinicians but require more involved
testing. Recently, measuring biomarkers of
T2 inflammation by focusing on peripheral
blood eosinophils has been used to direct
therapy and has become essential in the era
of biologically targeted therapies toward T2
inflammation in asthma (23).
Nitric oxide (NO) is a gas that can be
measured in the exhaled breath. Measuring
the fraction of this gas during a steady-state
exhalation, called the fractional exhaled NO
(FENO), is a standardized and quantitative
method for assessing the levels of this gas in
exhaled breath (24). The source of FENO
comes from the action of several different
NOS (NO synthase) enzymes, but the
principal source of the increased levels of
NO that are identified in asthma comes from
the iNOS2 (inducible NOS 2) enzyme that is
induced in the airway epithelium from
inflammation (25–27). Functions that have
been attributed to NO include actions as a
vasodilator, bronchodilator,
neurotransmitter, and mediator of
inflammation (28). A number of these roles
may be protective in nature, which led to
trials to augment the levels of NO in the
airways through the administration of
arginine and citrulline in selected individuals
with asthma (29, 30). There are also several
homeostatic functions attributed to NO,
including bactericidal and cytotoxic effects
that play a role in host defense (31). FENO
correlates well with airway eosinophilic
inflammation measured in induced sputum,
providing a noninvasive way to assess T2
airway inflammation in asthma (32–36).
Treatment with ICSs results in a marked
decrease in a subset of patients with ongoing
inflammation (37–39). There is strong
evidence that the levels of FENO correlate
with features of T2 inflammation,
particularly the levels of eosinophilia in
the peripheral blood and induced sputum
(34, 40). In individuals with atopic asthma,
FENO levels tend to correlate with elevated
total serum IgE levels or skin prick testing
results (41). Although FENO levels do not
correlate well with the degree of baseline
airflow obstruction, they tend to correlate
well with the severity and features of
“indirect” or “endogenous” AHR, such as
exercise-induced bronchoconstriction
(42–44). Interestingly, FENO levels change
dynamically after bronchoprovocation with
an initial decrease during airway narrowing
followed by an increase as the airways dilate
after the nadir during the late airway
response (45, 46).
Notably, an elevated FENO level is not
entirely specific to asthma and levels can be
elevated in people with atopy who do not
have other features of asthma (47, 48).
Recent studies have further delineated the
relationship between eosinophilic
inflammation and FENO by suggesting that
T2-targeted biological therapy that blocks IL-
13/IL-4 leads to a reduction in FENO levels
(49, 50–52) and that therapies targeting
eosinophils with anti–IL-5–directed
therapies may also lead to a reduction in
FENO levels (53–55).
After the initial development of using
FENO as a test, a clinical practice guideline
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Society (ATS) for the interpretation of FENO
in adults, which included general cut points
that represent a low FENO value as being
below 25 ppb and an elevated FENO value as
being above 50 ppb, whereas values between
25 and 50 ppb were considered
indeterminant (24). In children, the cut
points for FENO were slightly different: a low
FENO value is below 20 ppb, an elevated FENO
value is above 35 ppb, and values between 20
and 35 ppb were considered indeterminant
(24). Subsequent to this initial guideline,
several well-conducted studies have been
completed that have divided FENO values into
more narrowly defined ranges and have
ascertained the utility of this test relative to
multiple different outcomemeasurements
relevant to asthma.
Several key questions about the use of
FENO testing in clinical practice include the
use of this test as an aid in establishing the
diagnosis of asthma, for monitoring the
response to therapy, and for making initial
treatment decisions in an individual once the
diagnosis of asthma is established. Because of
this gap in knowledge, the ATS
commissioned a multidisciplinary panel to
select the single most important and
immediate question related to the use of the
FENO test to generate evidence-based
recommendations to improve patient-
centered outcomes. Several systematic
reviews have been published on the use of
FENO testing for asthma (56–60). These
analyses informed the panel’s decision
regarding the most critical question based on
the perceived impact on patient care, and the
panel subsequently selected the most
important outcomemeasures to evaluate the
use of FENO testing in clinical practice. These
results provide an evidence-based assessment
of the utility of the FENO test in the
management of individuals with asthma in
whom treatment is being contemplated and
are complementary to guidelines by the
National Asthma Education and Prevention
Program, the Global Initiative for Asthma
guidelines, and the Japanese Respiratory
Society guidelines (1, 2, 51).
Target Audience
This practice guideline is designed to
provide guidance to clinicians who manage
adults and children 4 years of age and older
with asthma, including adult and pediatric
pulmonologists, adult and pediatric
allergists, internists, pediatricians, family
medicine specialists, and other healthcare
providers involved in the care of patients
with asthma. The use of this guideline is not
designed for the evaluation and
management of acute asthma but rather is
designed for treatment decisions in
ambulatory settings for the ongoing
management of this common disease.
Methods
This clinical practice guideline was developed
in accordance with ATS policies and
procedures.
Panel Composition
This guideline was formulated by using a “top-
down” approach, with potential population,
intervention, comparator, and outcome
questions proposed by the Allergy,
Immunology, and Inflammation Assembly of
the ATS. Two co-chairs (S.B.K. and T.S.H.)
were selected by the ATSDocuments
Development Committee, and the overall
project was approved by the ATS Board of
Directors. Seventeen panel members were
selected on the basis of their expertise in adult
and pediatric asthma. The panel was assisted by
amethodology team composed of one senior
ATSmethodologist (J.M.I.) and two ATS
Methodology Scholars (I.S. and A. Barochia).
Conflict-of-Interest Declaration
and Management
All potential guideline panelists disclosed
their conflicts of interest according to ATS
policy, and disclosures were reviewed by ATS
staff and the ATS Conflict of Interest
Committee. There were no conflicts of
interests among any of the panelists, chairs,
or methodologists, and all were approved to
participate without limitations.
Meetings and Conference Calls
Panel members participated via
teleconference. Meetings of all panel
members were convened inMay, July, and
December of 2019 and in January of 2020.
Additional meetings were also held by the
co-chairs and the methodologists as needed
to resolve questions and provide guidance.
Formulation of Key Questions and
Selection of Outcomes of Interest
The panel discussed three population,
intervention, comparator, and outcome
questions proposed by the Allergy,
Immunology, and Inflammation Assembly
of the ATS. After discussion of the potential
questions, the panel formally voted and
chose the one question believed to be of the
highest priority for this guideline (Table 1).
The panel then selected patient-centric
outcomes relevant to FENO testing and voted
a priori to rank the importance of the
outcomes (Table 2). Outcomes were ranked
on a scale of 1–9, with scores of 1–3
considered of limited importance for
decision-making for this question, scores of
4–6 considered as important but not critical,
and scores of 7–9 considered critical for
decision-making (61). Outcomes with a
mean score of 7 or above were considered
critical and included asthma control as
assessed by using any validated
questionnaire, the use of oral corticosteroids,
the acute asthma exacerbation rate, the
frequency of emergency room/urgent care
visits, and the frequency of asthma-related
hospitalizations. The remaining outcomes,
including quality of life measures, symptom-
free days, days of work/school missed, daily
activities/exercise, use of ICSs, use of rescue
medications, patient satisfaction with care,
adverse events, medication adherence, cost-
effectiveness, lung function measures (FEV1
or FEV1/FVC ratio), blood eosinophils,
asthma-related mortality, asthmamedication
ratios, and inhaler techniques were
determined to be important but not critical
to decision-making for this question.
Evidence Review and Development of
Clinical Recommendations
The methodologists identified a prior
systematic review performed in 2016, which
was used in the development of a
comparative-effectiveness review by the
Agency for Healthcare Research and Quality
(AHRQ) (62). In addition to using the results
the aforementioned review, an additional
review of the literature was performed from
2016 through July 2019 by using the
Medline, Embase, and Cochrane Central
databases to identify relevant studies about
the effect of FENO-based care compared with
usual care on the outcomes of interest (see
Table E1 in the online supplement for the
search strategy). Titles and abstracts were
screened in duplicate by the senior
methodologist and an ATS scholar to
determine eligibility for inclusion on the
basis of predetermined criteria. All full-text
articles, including those included in the
AHRQ study, were then reviewed by the two
ATSMethodology Scholars (I.S. and A.
Barochia). The Preferred Reporting Items for
Systematic Reviews andMeta-Analyses
flowchart demonstrates the inclusion and
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exclusion criteria of the retrieved studies
(Figure 1) (63). The co-chairs and the panel
members were consulted to confirm
selection of the studies and suggested
additional studies not captured by the
literature review. After extracting relevant
data from each study, analysis was performed
for each outcome, with a meta-analysis being
performed, as appropriate, by using
Cochrane Collaboration ReviewManager
software, version 5.3 (64). If meta-analysis
could not be performed, a narrative review of
the results was provided.
A summary of the evidence was
prepared on the basis of the Grading of
Recommendations, Assessment,
Development, and Evaluation (GRADE)
approach by using the GRADEpro Guideline
Development Tool online application
(https://gradepro.org/) (65). Risk of bias in
the randomized controlled studies selected
was assessed by using the Cochrane
Collaboration’s risk of bias tool (66). The
confidence of the estimates was evaluated for
each outcome of interest by following the
GRADE approach (67). Certainty of the
evidence was categorized into four levels:
high, moderate, low, and very low.
The information was summarized in an
evidence-to-decision framework that
included a description of the desirable and
undesirable effects, the certainty of the
evidence, assumptions about patients’ values,
resource requirements, cost-effectiveness, the
potential effect on health equity, the
acceptability of the intervention by key
stakeholders, and the feasibility of
implementation (65).
Panel members reviewed the evidence
and discussed the evidence-to-decision
framework (Tables E2 and E3) via
teleconference in December of 2019 and
January of 2020. Subsequently, they
formulated the final recommendation and
approved it by consensus. As per the
GRADE approach, recommendations can be
labeled as either “strong” or “conditional.”
The panel was instructed to use the words
“we recommend” for strong
recommendations and “we suggest” for
conditional recommendations.
Manuscript Preparation
The initial draft of the manuscript was
written by the co-chairs with contributions
from all panel members. This draft was then
reviewed by the entire panel, providing an
opportunity to correct and supplement the
manuscript to accurately reflect discussions
and explanations for the key components of
the recommendation. The wording of the
final recommendation was not altered after
the recommendation was finalized. After
approval of the final manuscript by
consensus, it was submitted for external peer
review.
Peer Review
The guideline underwent anonymous peer
review by four content experts and one
methodologist. After multiple cycles of
review and revision, the guideline was
reviewed and approved by a
multidisciplinary board of directors. The
guideline will be reviewed by the ATS 3 years
after publication, and whether updating is
necessary will be determined.
Results
Question: Should patients with
asthma in whom treatment is being
contemplated undergo FENO testing?
Background. Our committee identified
high-priority outcome measurements to
assess the utility of measuring FENO in
patients with asthma in whom treatment is
being contemplated. Areas prioritized by
the committee reflect outcomes that
directly indicate uncontrolled asthma as
well as questionnaires that are designed to
assess asthma control. These areas were
prioritized primarily because they
Table 1. Questions Initially Proposed by the Guideline Co-Chairs and Question
Selection Results
Proposed Question Priority*
Should patients with asthma in whom treatment is being
contemplated undergo FENO testing?
10
Should patients being treated for asthma undergo FENO monitoring? 4
Should patients in whom a diagnosis of asthma is being considered
undergo FENO testing?
3
Definition of abbreviation: FENO= fractional exhaled nitric oxide.
*Number of panel members who selected this question as the highest priority.
Table 2. Prioritization of the Key Outcome Measurements for This Single-Question
Guideline
Outcome Measurement Mean SD Median IQR
Asthma control 7.94 2.49 8 2
Use of oral corticosteroids 7.93 2.74 8 0.5
Acute exacerbation rate 7.69 2.64 8.5 2
ER or urgent care visits 7.56 2.33 8 2
Hospitalizations due to asthma 7.25 1.99 8 2.25
Quality of life measures* 6.88 1.79 7 2
Symptom-free days 6.69 2.11 7 2
Days of work/school missed 6.69 2.28 7 2.25
Daily activities/exercise/sports 6.63 2.39 7 1.25
Use of inhaled corticosteroids 6.44 2.28 7 2
Use of rescue medications 6.38 1.72 6.5 3
Patient satisfaction with care 6.25 1.86 6.5 3
Medication-related adverse events 6.13 1.39 6.5 2.25
Medication adherence 6.06 1.30 6 4
Lung function measures† 5.63 2.91 5 1.25
Blood eosinophils 4.81 1.48 4.5 3.25
Asthma-related mortality 4.69 1.20 4.5 4.25
Asthma medication ratio 4.69 0.83 4 3.25
Inhalation technique 4.31 1.20 4.5 3.25
Definition of abbreviations: AQLQ=Asthma Quality of Life Questionnaire; ER=emergency
room; IQR= interquartile range.
*Any validated questionnaire or instrument (e.g., AQLQ or St. George’s questionnaire).
†FEV1 or FEV1/FVC ratio.
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represent the desired outcome of
appropriately applied therapy for asthma
to complement the more patient-centered
outcomes such as quality of life and
symptom-free days. In the clinic, asthma
control is often assessed by using validated
questionnaires, including the Asthma
Control Test (ACT) and the 7-item
Asthma Control Questionnaire (ACQ-7)
(68–70). Such patient-reported outcome
measures are considered to be clinically
relevant because they are strong predictors
of future exacerbations (71, 72). Further
evidence of asthma control may also be
determined from spirometry or other
surrogate lung function measurements.
Assessment of FENO in the clinic may be
complementary to these other assessment
tools, particularly if there is evidence that
the use of FENO-based care improves
specific outcomes that reflect asthma
control. In particular, the frequency of
exacerbations is a critical endpoint because
exacerbations cause significant morbidity,
cause mortality in some cases (73, 74), and
are associated with increased asthma-
related costs (75) and reduced long-term
lung function (76–78). Unscheduled visits
to the emergency department or urgent
care settings, overuse of short-acting
b-agonists, and frequent use of oral
corticosteroids similarly reflect evidence of
poor asthma control. Overall, therapies
such as ICSs have been shown to reduce
the frequency of exacerbations (6, 7);
however, whether an individual patient
should be treated with such a therapy and
the dose that is adequate to suppress
inflammation may not be apparent without
additional diagnostic tests because the
intensity of the disease varies from
individual to individual and the response
to therapy can be heterogeneous. The
expert panel therefore focused on these key
outcome measures and whether the
assessment of FENO during the evaluation
of an individual with asthma leads to a
significant change in these outcome
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Figure 1. Flowchart summarizing the workflow for the systematic review of the literature to identify studies relevant to this single-question
guideline. The methodologists used an existing comparative-effectiveness review as a starting point for the systematic review, which was
conducted by using relevant databases. The flowchart that overviews the inclusion and exclusion criteria is presented in the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses format. AHRQ=Agency for Healthcare Research and Quality.
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measures. These outcomes described in the
next section are available in Table E4,
which includes relevant forest plots that
display risk ratios for each outcome.
Validated questionnaires assessing
asthma control. The ACT and the ACQ-7
are both validated questionnaires that assess
asthma control (68–70). The results of these
simple assessment tools were viewed by the
panel as critical outcomemeasurements for
the utility of FENO assessment when
treatment is being contemplated. The two
different questionnaires could not be
combined into a single metric, and the
results did not identify evidence that FENO-
based care was associated with significant
changes in asthma control on the basis of
these questionnaires. Scores on the ACT
range from 5 to 25, with higher values (.19)
reflecting greater levels of asthma control.
The minimal important difference (MID) for
the ACT is around 3.0; however, the odds of
exacerbation and frequency of
bronchodilator use rise steeply when the
scores are below approximately 17 (70).
Although the mean difference (MD) in the
ACT score trended toward favoring FENO-
based care, this difference was not statistically
significant (MD, 0.40; 95% confidence
interval [CI],20.49 to 1.28). The trend
toward favoring FENO-based care as assessed
by using the ACT was entirely from one of
two studies, with no overall difference being
demonstrated in one study conducted in
adolescents and young adults (79) but an
overall difference being demonstrated in the
other study that was conducted in children
(80). Within the childhood study, the effect
was much stronger in the younger children
for whom the Childhood ACT was used to
monitor asthma control (69), with a 1.8-
point difference being demonstrated by using
the Childhood ACT (80).
The ACQ-7 is designed to identify
uncontrolled asthma, with values>1.5 being
associated with poor asthma control and
values<0.75 being associated with good
control (68). TheMID in this outcome is
around 0.5 (81). There was no overall
difference in the ACQ-7 scores between
FENO-based care and usual care (MD,20.01;
95% CI,20.19 to 0.16), and although there
was significant heterogeneity between the
studies, none of the effect sizes were close to
the MID of this instrument. The largest effect
favoring FENO-based care was in a trial that
enrolled patients with markedly uncontrolled
asthma at the onset of the study, with this
study reporting a significant difference in the
ACQ-7 results when using FENO-based care;
however, the differences in the ACQ-7 scores
between the groups were fairly small relative
to the marked improvement in asthma
control identified in both treatment groups
(82). The two other studies did not reveal a
difference with FENO-based care, although
asthma control was much better at baseline
in one study (83); in the other study, the
score on the ACQ-7 was used as part of the
algorithm to adjust asthma care (84).
Number and frequency of asthma
exacerbations. Acute asthma exacerbations
were viewed as a critical outcomemeasure.
Studies were identified that reported the
frequency of exacerbations (per patient per
year) and/or reported exacerbations as the
number of patients who experienced an
exacerbation and as the relative risk (RR).
There were 11 total studies that evaluated the
exacerbation frequency (39, 80, 83, 85–92),
but only 7 of these studies contributed to the
analysis because the variance was not
reported in all studies (39, 83, 85, 89–92).
Overall, there was a reduction in the
frequency of asthma exacerbations, favoring
FENO-based care (MD,20.15; 95% CI,20.28
to20.03). The largest effect size within a
single study was in a study conducted in
children (92); however, the majority of
studies contributing to these data reported
on either adults alone or adults and children
together. The overall certainty for the
frequency of exacerbations was
considered low.
The rate of exacerbations based on the
number of patients in each group was
reported in 10 studies with an overall
moderate certainty of the evidence (85,
87–95). The overall difference in the number
of patients experiencing an exacerbation was
significantly lower in the groups that received
FENO-based care (RR, 0.72; 95% CI, 0.56 to
0.93). This result translates on average to 111
fewer exacerbations per 1,000 individuals
(95% CI, 175 fewer to 28 fewer). It should be
noted that the majority of these studies were
conducted in children and that the results
favoring a reduction in the number of
exacerbations were not as strong in those
studies that enrolled adults (85, 89–91).
Oral corticosteroid use. The use of oral
corticosteroids was viewed as a critical
outcomemeasure by the panel because it
serves as a surrogate measure of exacerbation
frequency and severity, and the prevention of
oral corticosteroid-associated side effects by
dose reduction or omission is likely beneficial
to individuals with asthma. A total of six
studies were identified that reported on the
number of patients who used oral
corticosteroids in each treatment arm. In two
of the studies, the number was calculated
from the percentage (90, 93). The number of
patients treated with oral corticosteroids was
significantly reduced when FENO-based care
was used (RR, 0.79; 95% CI, 0.65 to 0.95).
This translates into 69 fewer individuals
using corticosteroids per 1,000 individuals
(95% CI, 115 fewer to 16 fewer). The
certainty of this finding was considered
moderate. It should be noted that a large
portion of the weight of the evidence came
from one study in children and adults (79)
and that four of the studies were conducted
entirely in children (93, 94, 96, 97), but all of
these studies were relatively small. All of the
included studies with the exception of one
small study (97) reported results that favored
FENO-based care.
Emergency room and unscheduled
healthcare visits. Emergency room visits,
unscheduled healthcare visits, and
hospitalizations for asthma were viewed by
the panel as critical outcomemeasures, but
there were relatively few data available for
each of these measures. Therefore, the
certainty of evidence was low to moderate.
Three studies reported emergency room and
unscheduled healthcare visits as the number
of patients in each arm (83, 87, 93), revealing
a nonsignificant reduction with using FENO-
based care (RR, 0.67; 95% CI, 0.37–1.22).
These studies included both children and
adults. Hospitalization for asthma is a
relatively rare event, and this outcome was
only reported in five studies (79, 83, 87, 88,
93); furthermore, the results could only be
combined from three studies (79, 83, 87).
Overall, there was no significant difference in
the frequency of asthma hospitalizations with
data derived from both children and adults
(RR, 0.78; 95% CI, 0.36–1.70).
Outcome measures that received a
lower priority. The panel ranked a number
of patient-centered outcomes as lower
priority than the five highest-priority
measurements. These patient-centered
outcomes included quality of life, symptom-
free days, days missed from work or school,
daily activities including exercise and sports,
and the use of rescue medications.
Three studies evaluated quality of life,
but data could not be combined because the
studies used slightly different outcome
measures. None of the studies showed a
significant difference in quality of life with
the intervention (83, 84, 96). Specifically, in
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adults, there was no difference in the Asthma
Quality of Life Questionnaire scores (MD, 0;
95% CI,20.29 to 0.29) (83) or in the
mini–Asthma Quality of Life Questionnaire
scores (MD, 0; 95% CI,20.49 to 0.49) (84),
whereas in studies enrolling children, there
was no difference in the Pediatric Asthma
Caregivers Quality of Life Questionnaire
scores (MD, 0; 95% CI,20.24 to 0.29) (96).
Only two studies reported symptom-free
days, and these data could not be pooled.
Both studies reported numeric
improvements in the frequency of symptom-
free days, with one study showing 4.1% more
symptom-free days (95% CI,212.8% to
21%) (87) and the other study showing 69%
versus 64% symptom-free days (P=0.44)
(90); however, these results were not
statistically significant. One study addressed
the frequency of days missed from school or
work, identifying anMD of 1.6 fewer days,
but this did not reach statistical significance
(95% CI,26.01 to 2.81 d) (83). No data were
identified on the effects on daily activity,
exercise, or sports participation.
Multiple studies reported ICS use;
however, the different medications and doses
that were administered did not allow pooling
of the data. The majority of the studies
showed no difference in ICS use (80, 83–86,
91, 94–96), but there was evidence in some
studies of increased ICS use (39, 87–89), and
a few studies showed less ICS use (90, 98).
Two studies evaluated rescue inhaler use, and
neither the individual studies nor the
combined data identified a significant effect
on rescue inhaler use (MD, 0.07; 95% CI,
20.16 to 0.30) (80, 90). The committee had
identified the asthmamedication ratio as a
key outcome measure (i.e., the ratio of ICSs
to short-acting b-agonists), but no data
could be identified. One study reported
medication adherence as an outcome
measure but did not identify a significant
difference in adherence (MD,20.2; 95% CI,
20.34 to 0.06) (83). Two other studies
reported the percentage of adherence in each
group, but neither identified a significant
difference (80, 90).
Although the panel generally ranked
lung function measurements as being lower
in priority than other measures, 11 studies
reported spirometry testing (79, 80, 82–84,
86–88, 90, 96), and the results of nine of
these studies could be pooled for analysis
that used the percent change in the FEV1 as
the primary outcome (79, 80, 82–84, 86, 87,
90, 96). The results demonstrate an overall
improvement in lung function when FENO-
based care was used, but the effect size was
small (MD, 1.11%; 95% CI, 0.02–2.21%).
There was some heterogeneity in the studies,
with one pediatric study showing anMD of
4.9% (84); there was no obvious difference
overall between pediatric and adult studies,
which were equally represented among the
results. Although the effect size was small
and it is uncertain whether this difference is
meaningful to individual patients with
asthma, these results may provide additional
evidence that FENO-based care can be used to
optimize the dose of ICSs, a class of drugs
known to improve baseline lung function in
asthma (99).
Patient satisfaction with care and
adverse events related to medications both
received moderate priority by the panel. One
study that focused on homemonitoring of
FENO, spirometry, and symptoms to facilitate
tapering of oral corticosteroids reported that
satisfaction with care on a scale of 1–7 was
actually lower in the intervention group
receiving FENO testing, but this difference did
not reach statistical significance (MD, 0.5;
95% CI,21.03 to 0.03). Adverse events were
reported in four studies, but adverse events
were not reported in a manner that allowed
the data to be pooled. Two studies reported
adverse events in a manner that could be
pooled, but the frequency was low and not
necessarily related to the intervention (RR,
0.20; 95% CI, 0.04 to 0.98) (39, 80). The other
two studies reported no significant difference
in adverse events between the groups (79,
96). Three studies reported the percentage of
blood eosinophils, but results could not be
combined because of differences in
reporting; however, no differences in the
peripheral blood eosinophil count were
identified (39, 82, 84).
Cost-effectiveness. We conducted a
limited pragmatic review of studies
addressing cost-effectiveness of the use of
FENO-based care to inform treatment
decisions. Eight studies were identified that
addressed cost-effectiveness (83, 100–106).
Although an initial evaluation of cost-
effectiveness concluded that the potential
costs outweigh the benefits (106), subsequent
analyses of the potential costs relative to the
benefits have generally favored the cost-
effectiveness of FENO-based care (102),
particularly in individuals who experience
exacerbations (101). Importantly, it should
be noted that a number of the studies
addressing costs also used FENO testing to
monitor disease (83, 103, 105), rather than to
answer the specific question addressed in this
guideline, but generally found that FENO-
based care was cost-effective or at least
comparable with other strategies (104). One
study reported that the use of FENO testing
could reduce the costs by identifying
potential responders to a T2 biologic (100).
Although these data are relatively limited, the
panel concluded that the available evidence
probably favors the intervention from a cost-
effectiveness standpoint.
Panel judgment. In patients with
asthma in whom treatment is being
contemplated, the panel believed that the
evidence favored the assessment of FENO
during evaluation of an individual with
asthma in addition to usual care. The
problem outlined in this question was
believed to be a priority by ATS leadership as
well as by the authors of guidelines on
asthma (1, 2). Further interest in this area
was reinforced by the frequency of citations
of the initial guideline for the use of FENO
testing (24) as well as of the recent analyses
conducted by the U.S. AHRQ (62) and a
recent systematic review conducted in
Europe (107). Although the desirable effects
of the intervention were relatively modest in
magnitude, the outcomemeasurements that
revealed a desirable effect were prioritized by
the panel before the analysis and
demonstrated reduced exacerbation
frequency (28.9% vs. 39.7%; RR, 0.73 [95%
CI, 0.62–0.86]) and oral corticosteroid use
(26.0% vs. 32.8%; RR, 0.79 [95% CI,
0.65–0.95]), two critical outcomes of asthma
management. The panel also noted that in
some of these critical outcomes, the results
favoring FENO testing were generally stronger
in the pediatric trials.
The panel also noted that there were no
differences in a number of patient-reported
outcomes, including measures of quality of
life, symptom-free days, missed days of work,
and patient satisfaction with care, although
the studies were underpowered for these
outcomes. Furthermore, there were no
differences in ICS use, rescue inhaler use,
medication adherence, or blood eosinophil
levels; however, the judgment of the panel
was that these measurements would not
necessarily be altered by the intervention, as
the intervention is primarily designed to
individualize treatment decisions. With
regard to the dose of ICSs, the majority of
studies showed no overall difference in the
dose of ICSs. Some studies reported that the
overall ICS dose actually increased, whereas a
small minority of studies reported an overall
ICS dose decrease. When considering the
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certainty of the evidence, the effects on
exacerbation frequency and oral
corticosteroid use were graded as moderate,
whereas other outcome measures that also
reflect asthma control were graded as having
low certainty.
The undesirable effects of the
intervention were generally deemed to be
trivial, with a low overall rate of adverse
events (RR, 0.20; 95% CI, 0.04 to 0.98) and
absolute effect of 55 fewer per 1,000 (95% CI,
66 fewer to 1 fewer) for FENO-based care
compared with usual care being
demonstrated. Although the availability of
this diagnostic test may be variable among
institutions, the resources required for this
test appear to be moderate in cost, although
resources such as operator training may be a
significant consideration depending on the
size of the center and the frequency with
which the test is conducted. The cost of the
test was another significant consideration;
however, our preliminary analysis of cost-
effectiveness probably favors the intervention
of FENO-based care, although study
methodologies and statistical modeling
approaches varied and certain subgroups in
which FENO testing may not be effective were
not delineated. The intervention was believed
to be acceptable to key stakeholders. Primary
care asthma clinics found it feasible and
acceptable among adults and children above
the age of 4 years, as did healthcare providers
managing pregnant patients with asthma
(108). Overall, the balance between desirable
and undesirable effects probably favored the
intervention, with the relative absence of a
downside and the potential to determine and
reduce exacerbations and reduce oral
corticosteroid use being shown.
ATS recommendation. In patients with
asthma in whom treatment is being
considered, we suggest the use of FENO
testing in addition to usual care over usual
care alone (conditional recommendation,
low confidence in estimates of effect).
Remarks. Despite nearly 10 years of
research since the initial guidelines in this
area were published, the available data from
randomized control trials remain fairly
limited, and some of the selected outcome
measures may not have had adequate power
to detect a difference. The consensus of the
group was that FENO-based care provides the
clinician with a simple and noninvasive
point-of-care test that provides
complementary information over usual care
and that the undesirable effects were small
relative to the potential benefit. Given the
relatively modest effect sizes and statistical
significance, it is reasonable for individual
groups of providers to weigh the potential
costs and administrative burden relative to
the benefits outlined in this guideline. In
addition to providers, stakeholders such as
individuals with asthma, payors, and the
Food and Drug Administration could
reasonably grade other outcomes such as
quality of life and symptom-free days as a
higher priority.
The recommendation places a high
value on asthma exacerbations and reduction
in need for oral corticosteroid use, which
were categorized as critical outcome
measures by this panel and other groups (1,
2). Although the balance of desirable and
undesirable effects probably favored the
intervention, it was noted by the group that
usual asthma care has evolved over the past
few years. Although phenotyping and
endotyping asthma have become paramount
in asthmamanagement, there have been no
studies to look at the additional benefit of
adding FENO testing once an asthma
phenotype has already been classified,
although there is some evidence that FENO
testing can be used as an assessment tool for
the use of biologics. Furthermore, it has not
been determined whether there are
subgroups in which FENOmeasurement
should not be used because the intervention
may not be cost-effective or beneficial for
achieving the desired outcomes.
Future research opportunities. There
are several limitations identified in this
report and other contemporary systematic
reviews regarding the use of FENO testing that
should be further evaluated. Larger
pragmatic randomized controlled trials that
are powered on the basis of the available
evidence should be conducted to more
clearly delineate the benefit of FENO-based
care in patients with asthma in whom
treatment is being considered. There is
similarly a need for larger trials that evaluate
the use of FENO testing to monitor therapy
with serial measurements once the FENO level
is established, and there is a need to better
delineate the potential diagnostic accuracy of
FENO testing as a tool to establish the
diagnosis of asthma. Timing of the initial
assessment of FENO is also uncertain because
there are anticipated differences between the
values when individuals with asthma are
medication naive and the values when
establishing the initial FENO value while
individuals are on a stable dose of therapy, as
was the case in the majority of trials
identified in this report.
Another area that requires further
investigation is specific subgroups with
asthma and the need to adequately power
future clinical studies and trials specifically
for analyses of these subgroups. Pertinent
subgroups include individuals with
T2-predominant asthma as well as
individuals with allergic sensitization, in
whom the value may be greater; however, the
value added to other currently used tests
such as those measuring peripheral blood
eosinophils and allergen-specific IgE needs
further delineation. Studies should also
further evaluate subgroups in which FENO-
based care may be less helpful, as there are
lower anticipated levels in subgroups such as
individuals with obesity-associated asthma
(109) and cigarette smokers (110–112).
There were also notable differences between
children and adults in the studies evaluated
for this guideline, indicating that larger
studies are needed to further define the
benefits within these different populations.
Discussion
The recommendations in this single-
question guideline were derived from our
systematic review of the available evidence
and our interpretation of how the evidence
may be applied in clinical practice. We gave a
conditional recommendation for the use of
FENO testing in addition to usual care in
patients with asthma in whom treatment is
being considered. This single-question
guideline incorporated a decision structure
in which experts in the FENO field initially
made a determination about the question
with greatest potential impact. An expert
panel including individuals with diverse
backgrounds in various practice settings and
in different regions of the world was
assembled to provide input about the
selection of the most important single
question and to identify the key outcome
measures. This guideline is not meant to be
all inclusive regarding the use of FENO testing
in clinical practice but was designed to
answer this single question in a timely
manner by using rigorous statistical methods
to evaluate the evidence.
The decision that was reached was
based primarily on the supportive evidence
of effects on the frequency and percentage of
asthma exacerbations as well as the need for
treatment with oral corticosteroids, which
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were deemed by the panel a priori to be
critical outcome measures. It should also be
noted that the summation of the evidence for
several other outcomemeasures that were
deemed a high priority by the panel—asthma
control as assessed by using validated
questionnaires and acute care visits for
asthma, including emergency department
visits, urgent care visits and
hospitalizations—did not reach statistical
significance, but each of these outcomes had
mean values that favored FENO-based care.
The conditional recommendation means
that there is some uncertainty that the
desirable consequences of the intervention
outweigh the undesirable consequences. This
decision means that most well-informed
patients would choose FENO-based care but
that a substantial minority of individuals
with asthmamay not desire this test and that
the decision to conduct this test in an
individual patient should be the result of an
informed discussion between that individual
and the provider.
An important caveat about the results of
our recommendation to use FENO testing
when treatment is considered for an
individual with asthma is that the precise
FENO value that should initiate a change in
decision-making regarding therapy for
asthma was not ascertained by the available
evidence. In the initial guidelines in this area,
a low FENO value of 25 ppb (20 ppb in
children) was considered evidence that a
response to the corticosteroids was unlikely,
a high FENO value above 50 ppb (35 ppb in
children) was considered evidence of a likely
corticosteroid response, and values between
these two boundaries were considered
indeterminate. Subsequent studies have used
muchmore narrowly defined ranges for
FENO values, with various algorithms being
used to make treatment decisions on the
basis of the results. Because of the variability
in these studies as well as the inherent
phenotypic variability of asthma, it was the
consensus of the committee that the available
evidence did not provide enough data to
recommend specific cut points associated
with specific actions such as starting or
increasing the dose of an ICS. Although we
did not reach this aspirational goal, we
believe that the level of FENO should be
combined with other measures that are used
to assess asthma control and that the level of
FENO should be interpreted within this
context of the pretest probability (Figure 2).
This framework is similar to that of other
tests such as bronchoprovocation tests, in
which the pretest probability combined with
the degree of AHR act together to establish
the likelihood of asthma (113). The decision
of an individual clinician to use a lower FENO
value to identify persistent inflammation
means that the sensitivity to detect
inflammation is being prioritized over the
specificity that a change in treatment will
make a difference. Similarly, a decision to use
a higher FENO value assigns greater priority
to the specificity of the finding at the cost of
reducing sensitivity (62). The consensus of
the panel was to give the clinician latitude
within their own practice to use this
framework to make treatment decisions.
The panel also recognizes that the
landscape of asthma management is in
continual evolution. The majority of the
patients considered within these studies were
already being treated with a stable ICS dose at
study enrollment, meaning that the question
that was examined is most pertinent to the
decision-making that is often encountered
during subspecialty consultation for an
individual with asthma. Furthermore, it is
now common to evaluate individuals for
evidence of T2 biomarkers such as peripheral
blood eosinophils and serum total and
allergen-specific IgE (41). The value added for
the use of FENO testing in an individual who
has already undergone phenotyping for T2
asthma or other advanced testing such as
bronchoprovocation or assessment of induced
sputum eosinophils was not addressed in a
manner that was amenable to systematic
review. Furthermore, there is evidence that
some subgroups such as individuals with
asthma associated with obesity and
individuals who smoke cigarettes have lower
FENO values and that the value of FENO-based
care may be limited in these individuals
(109–112). It should also be noted that if such
individuals with low FENO values were
specifically excluded from the analysis, the
results could be more strongly in favor of the
use of FENO testing when making treatment
decisions in an individual with asthma.
Finally, we would like to reiterate that
we selected the single question with the
greatest significance to clinical practice as
perceived by our panel. Leadership in the
ATS also identified two additional questions
relevant to the use of FENO testing that were
not addressed in this guideline. In this regard,
we view our analysis as being complementary
to other broader guidelines on this topic.
The recommendations in this guideline
were reviewed by the ATS Quality
Improvement and Implementation
Committee and none are considered suitable
for performance measure development.
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Figure 2. Conceptual framework for the use of fractional exhaled nitric oxide (FENO) testing to
guide treatment decisions for individuals with asthma. The decision to act on an individual FENO
value in an individual patient requires that the clinician combine clinical judgments based on the
perceived probability of benefit, with particular attention being given to the key outcome
measures such as exacerbation risks that were assessed in this guideline. As the level of FENO
increases in value, the specificity for a step up in therapy increases, whereas accepting lower
values of FENO to make treatment decisions places a higher value on the sensitivity to detect the
possibility that a step up in therapy may impact asthma control.
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Hospital, Lund University, Lund, Sweden;
11Department of Respiratory Medicine, First
Faculty of Medicine, Charles University and
Thomayer Hospital, Prague, Czech Republic;
12Department of Clinical Pharmacy and
Pharmacology, University of Groningen,
Groningen, the Netherlands; 13Division of
Pulmonology, Allergy and Immunology,
Department of Pediatrics, Emory University,
Atlanta, Georgia; 14Pulmonary, Allergy, Sleep,
and Critical Care Section of Boston
University, Boston, Massachusetts; 15Division
of Pulmonary and Critical Care, Department
of Medicine, Larner College of Medicine,
University of Vermont, Burlington, Vermont;
16Division of Pulmonary, Critical Care, and
Sleep, Department of Medicine, University of
California Davis, Davis, California; 17Veterans
Affairs Northern California Health Care
System, Mather, California; 18Division of
Pulmonary and Critical Care Medicine,
Department of Medicine, University of
Rochester Medical Center, Rochester, New
York; 19Scottish Centre for Respiratory
Research, University of Dundee, Scotland,
United Kingdom; 20ExpertPFT, LLC,
Matthews, North Carolina; 21Division of
Pulmonary and Critical Care Medicine,
Department of Medicine, University of
California San Francisco, San Francisco,
California; 22Division of Pulmonary, Allergy
and Critical Care Medicine, Department of
Medicine, Duke University, Durham, North
Carolina; 23Division of Pulmonary, Allergy/
Immunology, and Sleep Medicine,
Department of Pediatrics, Case Western
Reserve University, Cleveland, Ohio;
24Department of Pharmacology and
Therapeutics, Lung Health Research Centre,
School of Biomedical Sciences, Faculty of
Medicine, Dentistry and Health Sciences,
University of Melbourne, Parkville, Victoria,
Australia; 25Department of Pulmonary
Medicine, Albert Einstein College of
Medicine, New York, New York; and
26Division of Allergy, Pulmonary, and Critical
Care Medicine, Department of Medicine,
School of Pharmacy and School of Medicine
and Public Health, University of Wisconsin-
Madison, Madison, Wisconsin
Author Disclosures: P.A. served on an
advisory committee for AstraZeneca and
GlaxoSmithKline; served as a consultant for
Advance Medical, AstraZeneca, and
GlaxoSmithKline; served as a speaker for
Advancing Knowledge in Healthcare Inc.,
AstraZeneca, GlaxoSmithKline, Medscape/
WebMD, MJH Life Sciences, Prime CME,
Projects in Knowledge, Rockpointe, and
Vindico CME; received research support from
AstraZeneca, Boehringer Ingelheim,
GlaxoSmithKline, NIH, Novartis, and
Regeneron; and received royalties from
UpToDate. R.A.C. served as a consultant for
Cohero Health; and received research support
from the American Lung Association ACRC,
Avillion, GlaxoSmithKline, and NHLBI. Z.D.
served as a speaker for Sanofi. D.A.K. served
as a consultant for Spiration; served on a data
and safety monitoring board for Acorda; and
served as a speaker for MGC
Pharmaceuticals. S.K. received research
support from GlaxoSmithKline and Sanofi; and
provided writing support for Boehringer
Ingelheim. B.J.L. served on an advisory
committee for AstraZeneca, Chiesi, Circassia,
Novartis, Sanofi, and Teva; served as a
consultant for AstraZeneca, Boehringer
Ingelheim, Chiesi, Cipla, Circassia, Genentech,
Lupin, Sanofi, Teva, and Vectura; served as a
speaker for AstraZeneca, Boehringer
Ingelheim, Chiesi, Circassia, Sanofi, Teva, and
Thorasys; received research support from
AstraZeneca, Boehringer Ingelheim, Chiesi,
Sanofi, and Teva; received travel support from
AstraZeneca, Chiesi, and Teva; and received
equipment from GlaxoSmithKline and
Thorasys. S.B.K., T.S.H., A. Barochia, A.
Brady, J.S.D., A.M.F., J.M.I., N.J.K., K.M., M.P.,
L.G.Q., K.R.R., E.K.S.-F., I.S., and C.A.S.
reported no commercial or relevant
noncommercial interests.
Acknowledgment: The co-chairs of the
committee thank Kevin Wilson for his
guidance on this new practice guideline
creation; their methodologists Drs. Iaccarino,
Barochia, and Soghier; and all members of
their highly engaged international team of
asthma specialists, clinicians, and scientists
who contributed significantly to their efforts
to provide a succinct document that guides
clinicians on the use of a exhaled nitric
oxide to guide the treatment of asthma and
highlight future directions for evaluation and
research.
References
1. Global strategy for asthma management and prevention. Fontana, WI:
Global Initiative for Asthma; 2019 [accessed 2020 Apr 1]. Available from:
https://ginasthma.org/.
2. National Asthma Education and Prevention Program. Expert panel report
3 (EPR-3): guidelines for the diagnosis and management of asthma:
summary report 2007. J Allergy Clin Immunol 2007;120:S94–S138.
[Published erratum appears in J Allergy Clin Immunol 121:1330].
3. Erle DJ, Sheppard D. The cell biology of asthma. J Cell Biol 2014;205:
621–631.
4. Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Pavord ID.
Optimal asthma control: time for a new target. Am J Respir Crit Care
Med 2020;201:1480–1487.
5. King-Biggs MB. Asthma. Ann Intern Med 2019;171:ITC49–ITC64.
6. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV,
et al.; START Investigators Group. Early intervention with budesonide in
mild persistent asthma: a randomised, double-blind trial. Lancet 2003;
361:1071–1076.
7. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and
the long term prevention of hospitalisation for asthma. Thorax 2002;57:
880–884.
8. Sorkness CA, Lemanske RF Jr, Mauger DT, Boehmer SJ, Chinchilli VM,
Martinez FD, et al.; Childhood Asthma Research and Education Network
of the NHLBI. Long-term comparison of 3 controller regimens for mild-
moderate persistent childhood asthma: the Pediatric Asthma Controller
Trial. J Allergy Clin Immunol 2007;119:64–72.
9. Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM,
et al.; Childhood Asthma Research and Education Network of the
NHLBI. Response profiles to fluticasone and montelukast in mild-to-
moderate persistent childhood asthma. J Allergy Clin Immunol 2006;117:
45–52.
10. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk
RC, et al. Characterization of within-subject responses to fluticasone
and montelukast in childhood asthma. J Allergy Clin Immunol 2005;115:
233–242.
11. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli
VM, et al.; Asthma Clinical Research Network of the National Heart
AMERICAN THORACIC SOCIETY DOCUMENTS
e106 American Journal of Respiratory and Critical Care Medicine Volume 204 Number 10 | November 15 2021
 
Lung, and Blood Institute. Significant variability in response to inhaled
corticosteroids for persistent asthma. J Allergy Clin Immunol 2002;109:
410–418.
12. Busse W, Raphael GD, Galant S, Kalberg C, Goode-Sellers S, Srebro S,
et al.; Fluticasone Propionate Clinical Research Study Group. Low-dose
fluticasone propionate compared with montelukast for first-line treatment
of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol
2001;107:461–468.
13. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pi~neiro A, Wei
LX, et al.; Montelukast/Beclomethasone Study Group. Oral
montelukast, inhaled beclomethasone, and placebo for chronic asthma:
a randomized, controlled trial. Ann Intern Med 1999;130:487–495.
14. Cowan DC, Taylor DR, Peterson LE, Cowan JO, Palmay R, Williamson
A, et al. Biomarker-based asthma phenotypes of corticosteroid
response. J Allergy Clin Immunol 2015;135:877–883, e1.
15. Demarche SF, Schleich FN, Paulus VA, Henket MA, Van Hees TJ, Louis
RE. Asthma control and sputum eosinophils: a longitudinal study in
daily practice. J Allergy Clin Immunol Pract 2017;5:1335–1343, e5.
16. Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Boushey HA, Chinchilli
VM, et al.; Asthma Clinical Research Network, NHLBI/NIH. Sputum
eosinophil counts predict asthma control after discontinuation of inhaled
corticosteroids. J Allergy Clin Immunol 2005;115:720–727.
17. Fleming L, Wilson N, Regamey N, Bush A. Use of sputum eosinophil
counts to guide management in children with severe asthma. Thorax
2012;67:193–198.
18. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E,
et al. Determining asthma treatment by monitoring sputum cell counts:
effect on exacerbations. Eur Respir J 2006;27:483–494.
19. Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB,
et al. Predictive markers of asthma exacerbation during stepwise dose
reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001;
163:406–412.
20. Clearie KL, Jackson CM, Fardon TC, Williamson PA, Vaidyanathan S,
Burns P, et al. Supervised step-down of inhaled corticosteroids in the
community: an observational study. Respir Med 2011;105:558–565.
21. Lipworth BJ, Short PM, Williamson PA, Clearie KL, Fardon TC, Jackson
CM. A randomized primary care trial of steroid titration against mannitol
in persistent asthma: STAMINA trial. Chest 2012;141:607–615.
22. Higgins BG, Britton JR, Chinn S, Cooper S, Burney PG, Tattersfield AE.
Comparison of bronchial reactivity and peak expiratory flow variability
measurements for epidemiologic studies. Am Rev Respir Dis 1992;145:
588–593.
23. McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma.
Am J Respir Crit Care Med 2019;199:433–445.
24. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO,
et al.; American Thoracic Society Committee on Interpretation of
Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications. An official
ATS clinical practice guideline: interpretation of exhaled nitric oxide
levels (FeNO) for clinical applications. Am J Respir Crit Care Med
2011;184:602–615.
25. Lane C, Knight D, Burgess S, Franklin P, Horak F, Legg J, et al. Epithelial
inducible nitric oxide synthase activity is the major determinant of nitric
oxide concentration in exhaled breath. Thorax 2004;59:757–760.
26. Roos AB, Mori M, Gr€onneberg R, €Osterlund C, Claesson HE, Wahlstr€om
J, et al. Elevated exhaled nitric oxide in allergen-provoked asthma is
associated with airway epithelial iNOS. PLoS One 2014;9:e90018.
27. Guo FH, Comhair SA, Zheng S, Dweik RA, Eissa NT, Thomassen MJ,
et al. Molecular mechanisms of increased nitric oxide (NO) in asthma:
evidence for transcriptional and post-translational regulation of NO syn-
thesis. J Immunol 2000;164:5970–5980.
28. van der Vliet A, Eiserich JP, Cross CE. Nitric oxide: a pro-inflammatory
mediator in lung disease? Respir Res 2000;1:67–72.
29. Liao SY, Showalter MR, Linderholm AL, Franzi L, Kivler C, Li Y, et al. L-
Arginine supplementation in severe asthma. JCI Insight 2020;5:137777.
30. Holguin F, Grasemann H, Sharma S, Winnica D, Wasil K, Smith V, et al.
L-Citrulline increases nitric oxide and improves control in obese
asthmatics. JCI Insight 2019;4:e131733.
31. Fang FC. Perspectives series: host/pathogen interactions. Mechanisms of
nitric oxide-related antimicrobial activity. J Clin Invest 1997;99:2818–2825.
32. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation
between exhaled nitric oxide, sputum eosinophils, and methacholine
responsiveness in patients with mild asthma. Thorax 1998;53:91–95.
33. Brightling CE, Symon FA, Birring SS, Bradding P, Wardlaw AJ, Pavord
ID. Comparison of airway immunopathology of eosinophilic bronchitis
and asthma. Thorax 2003;58:528–532.
34. Silkoff PE, Lent AM, Busacker AA, Katial RK, Balzar S, Strand M, et al.
Exhaled nitric oxide identifies the persistent eosinophilic phenotype in
severe refractory asthma. J Allergy Clin Immunol 2005;116:1249–1255.
35. Wagener AH, de Nijs SB, Lutter R, Sousa AR, Weersink EJ, Bel EH,
et al. External validation of blood eosinophils, FENO and serum periostin
as surrogates for sputum eosinophils in asthma. Thorax 2015;70:115–
120.
36. Gao J, Wu F. Association between fractional exhaled nitric oxide, sputum
induction and peripheral blood eosinophil in uncontrolled asthma.
Allergy Asthma Clin Immunol 2018;14:21.
37. Silkoff PE, McClean P, Spino M, Erlich L, Slutsky AS, Zamel N. Dose-
response relationship and reproducibility of the fall in exhaled nitric
oxide after inhaled beclomethasone dipropionate therapy in asthma
patients. Chest 2001;119:1322–1328.
38. Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-
Sheehan G, et al. Exhaled nitric oxide: a predictor of steroid response.
Am J Respir Crit Care Med 2005;172:453–459.
39. Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M,
et al.; Asthma Clinical Research Network of the NHLBI. Comparison of
physician-, biomarker-, and symptom-based strategies for adjustment of
inhaled corticosteroid therapy in adults with asthma: the BASALT ran-
domized controlled trial. JAMA 2012;308:987–997.
40. Fleming L, Tsartsali L, Wilson N, Regamey N, Bush A. Longitudinal
relationship between sputum eosinophils and exhaled nitric oxide in
children with asthma. Am J Respir Crit Care Med 2013;188:400–402.
41. Simpson A, Custovic A, Pipis S, Adisesh A, Faragher B, Woodcock A.
Exhaled nitric oxide, sensitization, and exposure to allergens in patients
with asthma who are not taking inhaled steroids. Am J Respir Crit Care
Med 1999;160:45–49.
42. Buchvald F, Hermansen MN, Nielsen KG, Bisgaard H. Exhaled nitric
oxide predicts exercise-induced bronchoconstriction in asthmatic school
children. Chest 2005;128:1964–1967.
43. ElHalawani SM, Ly NT, Mahon RT, Amundson DE. Exhaled nitric oxide
as a predictor of exercise-induced bronchoconstriction. Chest 2003;124:
639–643.
44. Manoharan A, Lipworth BJ, Craig E, Jackson C. The potential role of
direct and indirect bronchial challenge testing to identify overtreatment
of community managed asthma. Clin Exp Allergy 2014;44:1240–1245.
45. Boot JD, Tarasevych S, Sterk PJ, Schoemaker RC, Wang L, Amin D,
et al. Reversal of the late asthmatic response increases exhaled nitric
oxide. Respir Med 2005;99:1591–1594.
46. Khatri SB, Hammel J, Kavuru MS, Erzurum SC, Dweik RA. Temporal
association of nitric oxide levels and airflow in asthma after whole lung
allergen challenge. J Appl Physiol (1985) 2003;95:436–440, discussion
435.
47. Kurukulaaratchy RJ, Zhang H, Patil V, Raza A, Karmaus W, Ewart S,
et al. Identifying the heterogeneity of young adult rhinitis through cluster
analysis in the Isle of Wight birth cohort. J Allergy Clin Immunol 2015;
135:143–150.
48. Scott M, Raza A, Karmaus W, Mitchell F, Grundy J, Kurukulaaratchy RJ,
et al. Influence of atopy and asthma on exhaled nitric oxide in an
unselected birth cohort study. Thorax 2010;65:258–262.
49. Diamant Z, Vijverberg S, Alving K, Bakirtas A, Bjermer L, Custovic A,
et al. Toward clinically applicable biomarkers for asthma: an EAACI
position paper. Allergy 2019;74:1835–1851.
50. Arron JR, Choy DF, Scheerens H, Matthews JG. Noninvasive biomarkers
that predict treatment benefit from biologic therapies in asthma. Ann Am
Thorac Soc 2013;10:S206–S213.
51. Matsunaga K, Kuwahira I, Hanaoka M, Saito J, Tsuburai T, Fukunaga K,
et al.; Japanese Respiratory Society Assembly on Pulmonary
Physiology. An official JRS statement: the principles of fractional
exhaled nitric oxide (FeNO) measurement and interpretation of the
results in clinical practice. Respir Investig 2021;59:34–52.
52. Voraphani N, Gladwin MT, Contreras AU, Kaminski N, Tedrow JR,
Milosevic J, et al. An airway epithelial iNOS-DUOX2-thyroid peroxidase
metabolome drives Th1/Th2 nitrative stress in human severe asthma.
Mucosal Immunol 2014;7:1175–1185.
53. Sposato B, Camiciottoli G, Bacci E, Scalese M, Carpagnano GE, Pelaia
C, et al. Mepolizumab effectiveness on small airway obstruction,
AMERICAN THORACIC SOCIETY DOCUMENTS
American Thoracic Society Documents e107
 
corticosteroid sparing and maintenance therapy step-down in real life.
Pulm Pharmacol Ther 2020;61:101899.
54. Numata T, Nakayama K, Utsumi H, Kobayashi K, Yanagisawa H,
Hashimoto M, et al. Efficacy of mepolizumab for patients with severe
asthma and eosinophilic chronic rhinosinusitis. BMC Pulm Med 2019;
19:176.
55. Caminati M, Cegolon L, Vianello A, Chieco Bianchi F, Festi G, Marchi
MR, et al. Mepolizumab for severe eosinophilic asthma: a real-world
snapshot on clinical markers and timing of response. Expert Rev Respir
Med 2019;13:1205–1212.
56. Bjermer L, Alving K, Diamant Z, Magnussen H, Pavord I, Piacentini G,
et al. Current evidence and future research needs for FeNO
measurement in respiratory diseases. Respir Med 2014;108:830–841.
57. Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on
eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a
systematic review and meta-analysis. Thorax 2018;73:1110–1119.
58. Song WJ, Kim HJ, Shim JS, Won HK, Kang SY, Sohn KH, et al.
Diagnostic accuracy of fractional exhaled nitric oxide measurement in
predicting cough-variant asthma and eosinophilic bronchitis in adults
with chronic cough: a systematic review and meta-analysis. J Allergy
Clin Immunol 2017;140:701–709.
59. Tang S, Xie Y, Yuan C, Sun X, Cui Y. Fractional exhaled nitric oxide for
the diagnosis of childhood asthma: a systematic review and meta-
analysis. Clin Rev Allergy Immunol 2019;56:129–138.
60. Karrasch S, Linde K, R€ucker G, Sommer H, Karsch-V€olk M, Kleijnen J,
et al. Accuracy of FeNO for diagnosing asthma: a systematic review.
Thorax 2017;72:109–116.
61. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al.
GRADE guidelines: 2. Framing the question and deciding on important
outcomes. J Clin Epidemiol 2011;64:395–400.
62. Wang Z, Pianosi P, Keogh K, Zaiem F, Alsawas M, Alahdab F, et al. The
clinical utility of fractional exhaled nitric oxide (FeNO) in asthma
management. Rockville, MD: Agency for Healthcare Research and
Quality; 2017.
63. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. BMJ 2009;339:b2535.
64. Review Manager (RevMan). Version 5.3. Copenhagen, Denmark: Nordic
Cochrane Centre, Cochrane Collaboration; 2014 [accessed 2020 Aug
13]. Available from: https://training.cochrane.org/online-learning/core-
software-cochrane-reviews/revman.
65. Evidence Prime, Inc. GRADEpro GDT: GRADEpro guideline
development tool. Hamilton, ON, Canada: McMaster University; 2015
[accessed 2020 Aug 13]. Available from: https://gradepro.org/.
66. Higgins JP, Altman DG, Gøtzsche PC, J€uni P, Moher D, Oxman AD,
et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods
Group. The Cochrane Collaboration’s tool for assessing risk of bias in
randomised trials. BMJ 2011;343:d5928.
67. Balshem H, Helfand M, Sch€unemann HJ, Oxman AD, Kunz R, Brozek J,
et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin
Epidemiol 2011;64:401–406.
68. Juniper EF, Bousquet J, Abetz L, Bateman ED; GOAL Committee.
Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the
Asthma Control Questionnaire. Respir Med 2006;100:616–621.
69. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, et al.
Development and cross-sectional validation of the Childhood Asthma
Control Test. J Allergy Clin Immunol 2007;119:817–825.
70. Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The
minimally important difference of the Asthma Control Test. J Allergy
Clin Immunol 2009;124:719–723, e1.
71. Meltzer EO, Busse WW, Wenzel SE, Belozeroff V, Weng HH, Feng J,
et al. Use of the Asthma Control Questionnaire to predict future risk of
asthma exacerbation. J Allergy Clin Immunol 2011;127:167–172.
72. Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears MR,
et al. Overall asthma control: the relationship between current control
and future risk. J Allergy Clin Immunol 2010;125:600–608, e1–e6.
73. Bourdin A, Bjermer L, Brightling C, Brusselle GG, Chanez P, Chung KF,
et al. ERS/EAACI statement on severe exacerbations in asthma in
adults: facts, priorities and key research questions. Eur Respir J 2019;
54:1900900.
74. Sears MR. Epidemiology of asthma exacerbations. J Allergy Clin
Immunol 2008;122:662–668.
75. Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA,
McLaurin K. Effect of asthma exacerbations on health care costs
among asthmatic patients with moderate and severe persistent asthma.
J Allergy Clin Immunol 2012;129:1229–1235.
76. Calhoun WJ, Haselkorn T, Miller DP, Omachi TA. Asthma exacerbations
and lung function in patients with severe or difficult-to-treat asthma. J
Allergy Clin Immunol 2015;136:1125–1127, e4.
77. O’Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW; START
Investigators Group. Severe exacerbations and decline in lung function
in asthma. Am J Respir Crit Care Med 2009;179:19–24.
78. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict
excess lung function decline in asthma. Eur Respir J 2007;30:452–456.
79. Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O’Connor GT, Morgan
WJ, et al. Management of asthma based on exhaled nitric oxide in
addition to guideline-based treatment for inner-city adolescents and
young adults: a randomised controlled trial. Lancet 2008;372:1065–1072.
80. Voorend-van Bergen S, Vaessen-Verberne AA, Brackel HJ, Landstra AM,
van den Berg NJ, Hop WC, et al. Monitoring strategies in children with
asthma: a randomised controlled trial. Thorax 2015;70:543–550.
81. Juniper EF, Svensson K, M€ork AC, Ståhl E. Measurement properties and
interpretation of three shortened versions of the asthma control
questionnaire. Respir Med 2005;99:553–558.
82. Wang X, Wu L, Zhang Z, Kong Q, Qi H, Lei H. The reliability of adjusting
stepped care based on FeNO monitoring for patients with chronic
persistent asthma. Open Med (Wars) 2019;14:217–223.
83. Honkoop PJ, Loijmans RJ, Termeer EH, Snoeck-Stroband JB, van den
Hout WB, Bakker MJ, et al.; Asthma Control Cost-Utility Randomized
Trial Evaluation (ACCURATE) Study Group. Symptom- and fraction of
exhaled nitric oxide-driven strategies for asthma control: a cluster-
randomized trial in primary care. J Allergy Clin Immunol 2015;135:682–
688, e11.
84. Bernholm KF, Homøe AS, Meteran H, Jensen CB, Porsbjerg C, Backer
V. FENO-based asthma management results in faster improvement of
airway hyperresponsiveness. ERJ Open Res 2018;4:00147-2017.
85. Garg Y, Kakria N, Katoch CDS, Bhattacharyya D. Exhaled nitric oxide as
a guiding tool for bronchial asthma: a randomised controlled trial.Med J
Armed Forces India 2020;76:17–22.
86. Malerba M, Radaeli A, Olivini A, Ragnoli B, Ricciardolo F, Montuschi P.
The combined impact of exhaled nitric oxide and sputum eosinophils
monitoring in asthma treatment: a prospective cohort study. Curr Pharm
Des 2015;21:4752–4762.
87. Peirsman EJ, Carvelli TJ, Hage PY, Hanssens LS, Pattyn L, Raes MM,
et al. Exhaled nitric oxide in childhood allergic asthma management: a
randomised controlled trial. Pediatr Pulmonol 2014;49:624–631.
88. Petsky HL, Li AM, Au CT, Kynaston JA, Turner C, Chang AB.
Management based on exhaled nitric oxide levels adjusted for atopy
reduces asthma exacerbations in children: a dual centre randomized
controlled trial. Pediatr Pulmonol 2015;50:535–543.
89. Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ,
et al. The use of exhaled nitric oxide to guide asthma management: a
randomized controlled trial. Am J Respir Crit Care Med 2007;176:231–
237.
90. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of
exhaled nitric oxide measurements to guide treatment in chronic
asthma. N Engl J Med 2005;352:2163–2173.
91. Syk J, Malinovschi A, Johansson G, Unden AL, Andreasson A, Lekander
M, et al. Anti-inflammatory treatment of atopic asthma guided by
exhaled nitric oxide: a randomized, controlled trial. J Allergy Clin
Immunol Pract 2013;1:639–648, e1–e8.
92. Verini M, Consilvio NP, Di Pillo S, Cingolani A, Spagnuolo C, Rapino D,
et al. FeNO as a marker of airways inflammation: the possible
implications in childhood asthma management. J Allergy (Cairo) 2010;
2010:691425.
93. Morphew T, Shin HW, Marchese S, Pires-Barracosa N, Galant SP.
Phenotypes favoring fractional exhaled nitric oxide discordance vs
guideline-based uncontrolled asthma. Ann Allergy Asthma Immunol
2019;123:193–200.
94. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids
on exhaled nitric oxide in children with asthma: a randomized controlled
trial. Am J Respir Crit Care Med 2005;172:831–836.
95. Pike K, Selby A, Price S, Warner J, Connett G, Legg J, et al. Exhaled
nitric oxide monitoring does not reduce exacerbation frequency or
AMERICAN THORACIC SOCIETY DOCUMENTS
e108 American Journal of Respiratory and Critical Care Medicine Volume 204 Number 10 | November 15 2021
 
inhaled corticosteroid dose in paediatric asthma: a randomised
controlled trial. Clin Respir J 2013;7:204–213.
96. de Jongste JC, Carraro S, Hop WC, Baraldi E; CHARISM Study Group.
Daily telemonitoring of exhaled nitric oxide and symptoms in the
treatment of childhood asthma. Am J Respir Crit Care Med 2009;179:
93–97.
97. Fritsch M, Uxa S, Horak F Jr, Putschoegl B, Dehlink E, Szepfalusi Z,
et al. Exhaled nitric oxide in the management of childhood asthma: a
prospective 6-months study. Pediatr Pulmonol 2006;41:855–862.
98. Hashimoto S, Brinke AT, Roldaan AC, van Veen IH, M€oller GM, Sont JK,
et al. Internet-based tapering of oral corticosteroids in severe asthma: a
pragmatic randomised controlled trial. Thorax 2011;66:514–520.
99. Martin RJ, Szefler SJ, King TS, Kraft M, Boushey HA, Chinchilli VM,
et al.; NHLBI’s Asthma Clinical Research Center. The Predicting
Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin
Immunol 2007;119:73–80.
100. Brooks EA, Massanari M, Hanania NA, Weiner DJ. Cost-effectiveness
of fractional exhaled nitric oxide (FeNO) measurement in predicting
response to omalizumab in asthma. Clinicoecon Outcomes Res 2019;
11:301–307.
101. Brooks EA, Massanari M. Cost-effectiveness analysis of monitoring
fractional exhaled nitric oxide (FENO) in the management of asthma.
Manag Care 2018;27:42–48.
102. Arnold RJ, Massanari M, Lee TA, Brooks E. A review of the utility and
cost effectiveness of monitoring fractional exhaled nitric oxide (FENO) in
asthma management. Manag Care 2018;27:34–41.
103. Sabatelli L, Sepp€al€a U, Sastre J, Crater G. Cost-effectiveness and
budget impact of routine use of fractional exhaled nitric oxide monitoring
for the management of adult asthma patients in Spain. J Investig
Allergol Clin Immunol 2017;27:89–97.
104. Beerthuizen T, Voorend-van Bergen S, van den Hout WB, Vaessen-
Verberne AA, Brackel HJ, Landstra AM, et al. Cost-effectiveness of
FENO-based and web-based monitoring in paediatric asthma manage-
ment: a randomised controlled trial. Thorax 2016;71:607–613.
105. LaForce C, Brooks E, Herje N, Dorinsky P, Rickard K. Impact of
exhaled nitric oxide measurements on treatment decisions in an
asthma specialty clinic. Ann Allergy Asthma Immunol 2014;113:
619–623.
106. Franklin PJ, Stick SM. The value of FENO measurement in asthma
management: the motion against FENO to help manage childhood
asthma: reality bites. Paediatr Respir Rev 2008;9:122–126.
107. Essat M, Harnan S, Gomersall T, Tappenden P, Wong R, Pavord I,
et al. Fractional exhaled nitric oxide for the management of asthma in
adults: a systematic review. Eur Respir J 2016;47:751–768.
108. Pijnenburg MW, Lissenberg ET, Hofhuis W, Ghiro L, Ho WC,
Holland WP, et al. Exhaled nitric oxide measurements with dynamic
flow restriction in children aged 4-8 yrs. Eur Respir J 2002;20:
919–924.
109. Holguin F, Comhair SA, Hazen SL, Powers RW, Khatri SS, Bleecker
ER, et al. An association between L-arginine/asymmetric dimethyl
arginine balance, obesity, and the age of asthma onset phenotype. Am
J Respir Crit Care Med 2013;187:153–159.
110. McSharry CP, McKay IC, Chaudhuri R, Livingston E, Fraser I, Thomson
NC. Short and long-term effects of cigarette smoking independently
influence exhaled nitric oxide concentration in asthma. J Allergy Clin
Immunol 2005;116:88–93.
111. Michils A, Louis R, Peche R, Baldassarre S, Van Muylem A. Exhaled
nitric oxide as a marker of asthma control in smoking patients. Eur
Respir J 2009;33:1295–1301.
112. Nadif R, Matran R, Maccario J, Bechet M, Le Moual N, Scheinmann P,
et al. Passive and active smoking and exhaled nitric oxide levels
according to asthma and atopy in adults. Ann Allergy Asthma Immunol
2010;104:385–393.
113. Coates AL, Wanger J, Cockcroft DW, Culver BH, Carlsen K-H, Diamant
Z, et al.; Bronchoprovocation Testing Task Force. ERS technical
standard on bronchial challenge testing: general considerations and
performance of methacholine challenge tests. Eur Respir J 2017;49:
1601526.
AMERICAN THORACIC SOCIETY DOCUMENTS
American Thoracic Society Documents e109
 
